/PRNewswire/ Evogene Ltd. (NASDAQ: EVGN) (TASE: EVGN), a leading computational biology company targeting to revolutionize life-science product discovery and.
Lavie Bio Provides Product Pipeline Update for 2020
USA - English
News provided by
Share this article
Share this article
REHOVOT, Israel, Dec. 29, 2020 /PRNewswire/ Lavie Bio Ltd. (Lavie Bio), a leading ag-biologicals company focusing on improving food quality, sustainability and agriculture productivity through the introduction of microbiome-based products, and a subsidiary of Evogene Ltd. (NASDAQ: EVGN) (TASE: EVGN), has announced an update on certain advancements achieved in its pipeline in 2020, including phase advancement of bio-stimulant LAV211, towards an anticipated commercial launch in 2022.
Lavie Bio Logo
Evogene Logo Our commitment and main focus at Lavie Bio is to develop novel microbiome based ag-biological products, bio-pesticides & bio-stimulants that address the dire need for new tools to increase agriculture productivity while improving sustainability and food quality. 2020 was a remarkable year in our journey to achieve these targets, stated
Canonic : Announces Signing of First Cultivation Agreement for its Medical Cannabis Varieties marketscreener.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from marketscreener.com Daily Mail and Mail on Sunday newspapers.
Canonic Announces Signing of First Cultivation Agreement for its Medical Cannabis Varieties
USA - English
News provided by
Share this article
Share this article
REHOVOT, Israel, Dec. 23, 2020 /PRNewswire/ Canonic Ltd, a company focused on the development of medical cannabis products and a wholly owned subsidiary of Evogene Ltd. (NASDAQ: EVGN) (TASE: EVGN) announced today that it has signed its first commercial agreement with a licensed medical cannabis cultivator, Telcann Ltd, for the provision of plant growth services in Israel to Canonic. With this agreement, Canonic has completed the establishment of the major component required for the production infrastructure of its medical cannabis products,
Share this article
Share this article
REHOVOT, Israel, Dec. 15, 2020 /PRNewswire/ AgPlenus Ltd., an innovative company designing effective, sustainable crop protection products by leveraging computational biology and chemistry, and a subsidiary of Evogene Ltd. (NASDAQ: EVGN) (TASE: EVGN), announced today that it has reached the Lead stage in its novel Mode-of-Action (MoA) herbicide program. The achievement of this milestone follows the conclusion of field tests that demonstrated that product candidate APH1, at commercial dose rates, effectively controlled a broad panel of weeds, including weeds that are known to have resistance to existing herbicides. These results were confirmed in independent field tests conducted by SynTech Research, an agricultural R&D contract research organization located in California.